Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
ClinicalTrials.gov ID: NCT06283550
Sponsor: Innovaderm Research Inc.
Information provided by: Innovaderm Research Inc. (Responsible Party)
Last Update Posted: 2024-02-29
Brief Summary:
This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.
Detailed Description:
This randomized, double-blind, placebo-controlled, multicenter, phase 2 study aims to evaluate the efficacy of abrocitinib in 84 adult subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.
Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Intervention / Treatment:
- Drug: Abrocitinib 200 mg
- Drug: Abrocitinib 100 mg
- Drug: Placebo
Category | Value |
---|---|
Study Start (Estimated) | 2024-04 |
Primary Completion (Estimated) | 2025-05 |
Study Completion (Estimated) | 2025-08 |
Enrollment (Estimated) | 84 |
Study Type | Interventional |
Phase | Phase 2 |
Other Study ID Numbers |
INNO-6052
|